MARKET

MRTX

MRTX

Mirati
NASDAQ

Real-time Quotes | Nasdaq Last Sale

76.30
-4.12
-5.12%
After Hours: 76.30 0 0.00% 16:56 03/27 EDT
OPEN
77.42
PREV CLOSE
80.42
HIGH
79.90
LOW
75.71
VOLUME
367.37K
TURNOVER
--
52 WEEK HIGH
132.59
52 WEEK LOW
55.11
MARKET CAP
3.32B
P/E (TTM)
-13.5020
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of MRTX and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 15 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average MRTX stock price target is 115.43 with a high estimate of 134.00 and a low estimate of 68.00.

EPS

MRTX News

More
  • Is Mirati Therapeutics, Inc. (MRTX) A Good Stock To Buy?
  • Insider Monkey · 2d ago
  • Top Drug Stocks Under $5
  • MotleyFool.com · 3d ago
  • Benzinga's Top Upgrades, Downgrades For March 12, 2020
  • Benzinga · 03/12 13:57
  • Baird cuts view on Teladoc in premarket analyst action
  • Seeking Alpha - Article · 03/12 12:11

Industry

Biotechnology & Medical Research
-2.43%
Pharmaceuticals & Medical Research
-0.87%

Hot Stocks

Symbol
Price
%Change

About MRTX

Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company develops product candidates to address the genetic and immunological promoters of cancer. Its clinical programs consist of two product candidates: MRTX849, a Kirsten Rat Sarcoma (KRAS) G12C inhibitor, and Sitravatinib, a multi-kinase inhibitor. Its KRAS inhibitor program is focused on the discovery and development of small molecule compounds that target KRAS G12C and G12D. MRTX849 is designed to inhibit KRAS G12C mutations which are present in non-small cell lung cancer (NSCLC) adenocarcinoma patients, colorectal cancer (CRC) patients, pancreatic cancer patients, as well as several other difficult-to-treat cancers. Sitravatinib is a spectrum-selective kinase inhibitor designed to inhibit receptor tyrosine kinases (RTKs), including TAM family receptors (TYRO3, Axl, Mer), split family receptors (VEGFR2, KIT) and RET.
More

Webull offers kinds of Mirati Therapeutics Inc stock information, including NASDAQ:MRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRTX stock news, and many more online research tools to help you make informed decisions.